Current Treatment of Anal Squamous Cell Carcinoma

Hematology/Oncology Clinics of North America

Volumn 26, Issue 6, 2012, Pages 1315-1350

  Glynne Jones, Rob ^a   Renehan, Andrew ^b,c  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Chemoradiotherapy; Human papilloma virus; Salvage surgery; Squamous cell carcinoma of the anus

Indexed keywords

EID: 84868239326     PISSN: 08898588     EISSN: 15581977     Source Type: Journal    
DOI: 10.1016/j.hoc.2012.08.011     Document Type: Review

References (165)

1. Siegel R., Ward E., Brawley O., et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61(4):212-236.
2. Office of National Statistics. Cancer registration statistics: four-digit codes. 2007. Available at: Accessed May 30, 2010. http://www.statistics.gov.uk/StatBase/Product.asp%3fvlnk%3d7720.
3. Frisch M., Melbye M., Moller H. Trends in incidence of anal cancer in Denmark. BMJ 1993, 306(6875):419-422.
4. Goldman S., Glimelius B., Nilsson B., et al. Incidence of anal epidermoid carcinoma in Sweden 1970-1984. Acta Chir Scand 1989, 155(3):191-197.
5. Brewster D.H., Bhatti L.A. Increasing incidence of squamous cell carcinoma of the anus in Scotland, 1975-2002. Br J Cancer 2006, 95(1):87-90.
6. Johnson L.G., Madeleine M.M., Newcomer L.M., et al. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer 2004, 101(2):281-288.
7. Chiao E.Y., Krown S.E., Stier E.A., et al. A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic. J Acquir Immune Defic Syndr 2005, 40(4):451-455.
8. Williams G.R., Lu Q.L., Love S.B., et al. Properties of HPV-positive and HPV-negative anal carcinomas. J Pathol 1996, 180(4):378-382.
9. Penn I. Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases. Cancer 1986, 58(3):611-616.
10. Sillman F.H., Sentovich S., Shaffer D. Ano-genital neoplasia in renal transplant patients. Ann Transplant 1997, 2(4):59-66.
11. Daling J.R., Sherman K.J., Hislop T.G., et al. Cigarette smoking and the risk of anogenital cancer. Am J Epidemiol 1992, 135(2):180-189.
12. Holly E.A., Whittemore A.S., Aston D.A., et al. Anal cancer incidence: genital warts, anal fissure or fistula, hemorrhoids, and smoking. J Natl Cancer Inst 1989, 81(22):1726-1731.
13. Nordenvall C., Nilsson P.J., Ye W., et al. Smoking, snus use and risk of right- and left-sided colon, rectal and anal cancer: a 37-year follow-up study. Int J Cancer 2011, 128(1):157-165.
14. Tseng H.F., Morgenstern H., Mack T.M., et al. Risk factors for anal cancer: results of a population-based case-control study. Cancer Causes Control 2003, 14(9):837-846.
15. Frisch M., Johansen C. Anal carcinoma in inflammatory bowel disease. Br J Cancer 2000, 83(1):89-90.
16. Frisch M., Olsen J.H., Melbye M. Malignancies that occur before and after anal cancer: clues to their etiology. Am J Epidemiol 1994, 140(1):12-19.
17. Silverberg M.J., Lau B., Justice A.C., et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis 2012, 54(7):1026-1034.
18. De Vuyst H., Clifford G.M., Nascimento M.C., et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer 2009, 124(7):1626-1636.
19. Bosch F.X., Manos M.M., Munoz N., et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995, 87(11):796-802.
20. Bjorge T., Engeland A., Luostarinen T., et al. Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study. Br J Cancer 2002, 87(1):61-64.
21. Palefsky J.M., Holly E.A., Ralston M.L., et al. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis 1998, 177(2):361-367.
22. Scholefield J.H., Castle M.T., Watson N.F. Malignant transformation of high-grade anal intraepithelial neoplasia. Br J Surg 2005, 92(9):1133-1136.
23. Clark M.A., Hartley A., Geh J.I. Cancer of the anal canal. Lancet Oncol 2004, 5(3):149-157.
24. Abbasakoor F., Boulos P.B. Anal intraepithelial neoplasia. Br J Surg 2005, 92(3):277-290.
25. Zbar A.P., Fenger C., Efron J., et al. The pathology and molecular biology of anal intraepithelial neoplasia: comparisons with cervical and vulvar intraepithelial carcinoma. Int J Colorectal Dis 2002, 17(4):203-215.
26. Dittmer D.P. An appraisal of non-AIDS-defining cancers: comment on "spectrum of cancer risk late after AIDS onset in the United States". Arch Intern Med 2010, 170(15):1345-1346.
27. Roden R., Wu T.C. How will HPV vaccines affect cervical cancer?. Nat Rev Cancer 2006, 6(10):753-763.
28. Palefsky J.M., Giuliano A.R., Goldstone S., et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011, 365(17):1576-1585.
29. Licitra L., Perrone F., Bossi P., et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006, 24(36):5630-5636.
30. Shi W., Kato H., Perez-Ordonez B., et al. Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol 2009, 27(36):6213-6221.
31. Mammas I.N., Sourvinos G., Giannoudis A., et al. Human papilloma virus (HPV) and host cellular interactions. Pathol Oncol Res 2008, 14(4):345-354.
32. Bartelink H., Roelofsen F., Eschwege F., et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997, 15(5):2040-2049.
33. Nilsson P.J., Svensson C., Goldman S., et al. Epidermoid anal cancer: a review of a population-based series of 308 consecutive patients treated according to prospective protocols. Int J Radiat Oncol Biol Phys 2005, 61(1):92-102.
34. Renehan A.G., Saunders M.P., Schofield P.F., et al. Patterns of local disease failure and outcome after salvage surgery in patients with anal cancer. Br J Surg 2005, 92:605-614.
35. UKCCCR Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996, 348(9034):1049-1054.
36. Ajani J.A., Winter K.A., Gunderson L.L., et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 2008, 299(16):1914-1921.
37. Das P., Cantor S.B., Parker C.L., et al. Long-term quality of life after radiotherapy for the treatment of anal cancer. Cancer 2010, 116(4):822-829.
38. Klas J.V., Rothenberger D.A., Wong W.D., et al. Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes. Cancer 1999, 85(8):1686-1693.
39. Deniaud-Alexandre E., Touboul E., Tiret E., et al. Results of definitive irradiation in a series of 305 epidermoid carcinomas of the anal canal. Int J Radiat Oncol Biol Phys 2003, 56(5):1259-1273.
40. Renehan A.G., O'Dwyer S.T. Initial management through the anal cancer multidisciplinary team meeting. Colorectal Dis 2011, 13(Suppl 1):21-28.
41. National Cancer Peer Review Programme Manual for cancer services 2008; colorectal measures 2010, NHS National Cancer Action Team, London.
42. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Anal carcinoma version 2.2012. 2011. Available at: Accessed May 16, 2012. http://www.nccn.org/professionals/physician_gls/pdf/anal.pdf.
43. Hill J., Meadows H., Haboubi N., et al. Pathological staging of epidermoid anal carcinoma for the new era. Colorectal Dis 2003, 5(3):206-213.
44. Wade D.S., Herrera L., Castillo N.B., et al. Metastases to the lymph nodes in epidermoid carcinoma of the anal canal studied by a clearing technique. Surg Gynecol Obstet 1989, 169(3):238-242.
45. Greenall M.J., Quan S.H., Urmacher C., et al. Treatment of epidermoid carcinoma of the anal canal. Surg Gynecol Obstet 1985, 161(6):509-517.
46. Fenger C., Frisch M., Marti M.C., et al. Tumours of the anal canal. World Health Organization classification of tumours. Pathology and genetics of tumours of the digestive system 2000, 145-155. IARC Press, Lyon (France). S.R. Hamilton, L.A. Aaltonen (Eds.).
47. Glynne-Jones R., Northover J.M., Cervantes A. Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl 5):v87-v92.
48. Shepherd N.A., Scholefield J.H., Love S.B., et al. Prognostic factors in anal squamous carcinoma: a multivariate analysis of clinical, pathological and flow cytometric parameters in 235 cases. Histopathology 1990, 16(6):545-555.
49. Lampejo T., Kavanagh D., Clark J., et al. Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review. Br J Cancer 2010, 103(12):1858-1869.
50. Ogunbiyi O.A., Scholefield J.H., Smith J.H., et al. Immunohistochemical analysis of p53 expression in anal squamous neoplasia. J Clin Pathol 1993, 46(6):507-512.
51. The tumour suppressor gene p53. Frontiers in molecular biology 1997, Oxford University Press, New York. S.A. Gangopadhyay, Y. Lin (Eds.).
52. Mawdsley S., Meadows H., James R. The role of biological molecular markers in predicting both response to treatment and clinical outcome in squamous cell carcinoma of the anus. ASCO 2004, [abstract 183], Gastrointestinal Cancers Symposium Proceedings, San Francisco, January 2004.
53. Allal A.S., Alonso-Pentzke L., Remadi S. Apparent lack of prognostic value of MIB-1 index in anal carcinomas treated by radiotherapy. Br J Cancer 1998, 77(8):1333-1336.
54. Noffsinger A.E., Hui Y.Z., Suzuk L., et al. The relationship of human papillomavirus to proliferation and ploidy in carcinoma of the anus. Cancer 1995, 75(4):958-967.
55. Renehan A.G., Yeh H.C., Johnson J.A., et al. Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia 2012, 55(6):1619-1632.
56. Edge S.B., Byrd D.R., Compton C.C., et al. AJCC cancer staging manual 2009, Springer, New York. 7th edition.
57. Roach S.C., Hulse P.A., Moulding F.J., et al. Magnetic resonance imaging of anal cancer. Clin Radiol 2005, 60(10):1111-1119.
58. Salerno G., Daniels I.R., Brown G. Magnetic resonance imaging of the low rectum: defining the radiological anatomy. Colorectal Dis 2006, 8(Suppl 3):10-13.
59. Koh D.M., Dzik-Jurasz A., O'Neill B., et al. Pelvic phased-array MR imaging of anal carcinoma before and after chemoradiation. Br J Radiol 2008, 81(962):91-98.
60. Engstrom P.F., Arnoletti J.P., Benson A.B., et al. NCCN clinical practice guidelines in oncology. Anal carcinoma. J Natl Compr Canc Netw 2010, 8(1):106-120.
61. Cotter S.E., Grigsby P.W., Siegel B.A., et al. FDG-PET/CT in the evaluation of anal carcinoma. Int J Radiat Oncol Biol Phys 2006, 65(3):720-725.
62. Krengli M., Milia M.E., Turri L., et al. FDG-PET/CT imaging for staging and target volume delineation in conformal radiotherapy of anal carcinoma. Radiat Oncol 2010, 5:10.
63. Winton E., Heriot A.G., Ng M., et al. The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer. Br J Cancer 2009, 100(5):693-700.
64. Trautmann T.G., Zuger J.H. Positron emission tomography for pretreatment staging and posttreatment evaluation in cancer of the anal canal. Mol Imaging Biol 2005, 7(4):309-313.
65. Bhuva N.J., Glynne-Jones R., Sonoda L., et al. To PET or not to PET? That is the question. Staging in anal cancer. Ann Oncol 2012, 23(8):2078-2082.
66. De La Rochefordière A., Pontvert D., Asselain B., et al. Radiothérapie des cancers du canal anal. Expérience de l'institut Curie dans le traitement des aires ganglionnaires. Bull Cancer Radiother 1993, 80:391-398.
67. Gerard J.P., Chapet O., Samiei F., et al. Management of inguinal lymph node metastases in patients with carcinoma of the anal canal: experience in a series of 270 patients treated in Lyon and review of the literature. Cancer 2001, 92(1):77-84.
68. Makela P.J., Leminen A., Kaariainen M., et al. Pretreatment sonographic evaluation of inguinal lymph nodes in patients with vulvar malignancy. J Ultrasound Med 1993, 12(5):255-258.
69. de Jong J.S., Beukema J.C., van Dam G.M., et al. Limited value of staging squamous cell carcinoma of the anal margin and canal using the sentinel lymph node procedure: a prospective study with long-term follow-up. Ann Surg Oncol 2010, 17(10):2656-2662.
70. Leichman L., Nigro N., Vaitkevicius V.K., et al. Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy. Am J Med 1985, 78(2):211-215.
71. Nigro N.D., Vaitkevicius V.K., Considine B. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum 1974, 17(3):354-356.
72. Cummings B.J., Keane T.J., O'Sullivan B., et al. Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-fluorouracil with and without mitomycin C. Int J Radiat Oncol Biol Phys 1991, 21(5):1115-1125. [see comments].
73. Newman G., Calverley D.C., Acker B.D., et al. The management of carcinoma of the anal canal by external beam radiotherapy, experience in Vancouver 1971-1988. Radiother Oncol 1992, 25(3):196-202.
74. Papillon J., Montbarbon J.F. Epidermoid carcinoma of the anal canal. A series of 276 cases. Dis Colon Rectum 1987, 30(5):324-333.
75. Glimelius B., Pahlman L. Radiation therapy of anal epidermoid carcinoma. Int J Radiat Oncol Biol Phys 1987, 13(3):305-312.
76. Eschwege F., Lasser P., Chavy A., et al. Squamous cell carcinoma of the anal canal: treatment by external beam irradiation. Radiother Oncol 1985, 3(2):145-150.
77. Cantril S.T., Green J.P., Schall G.L., et al. Primary radiation therapy in the treatment of anal carcinoma. Int J Radiat Oncol Biol Phys 1983, 9(9):1271-1278.
78. Cummings B.J., Keane T.J., O'Sullivan B., et al. Mitomycin in anal canal carcinoma. Oncology 1993, 50(Suppl 1):63-69.
79. Friberg B., Svensson C., Goldman S., et al. The Swedish National Care Programme for Anal Carcinoma-implementation and overall results. Acta Oncol 1998, 37(1):25-32.
80. John M., Pajak T., Flam M., et al. Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92-08. Cancer J Sci Am 1996, 2(4):205-211.
81. Martenson J.A., Lipsitz S.R., Lefkopoulou M., et al. Results of combined modality therapy for patients with anal cancer (E7283). An Eastern Cooperative Oncology Group study. Cancer 1995, 76(10):1731-1736.
82. Rich T.A., Hughes L., Ajani J.A., et al. Low dose, continuous infusion 5-fluorouracil plus radiotherapy for anal cancer. Int J Radiat Oncol Biol Phys 1990, 18(3):710.
83. Flam M., John M., Pajak T.F., et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996, 14(9):2527-2539.
84. Gunderson LL, Winter KA, Ajani JA, et al. Long-term update of US GI Intergroup RTOG- 98-11 phase III trial for anal carcinoma: comparison of concurrent chemoradiation with 5FU-mitomycin versus 5FU-cisplatin. Gastrointestinal Cancers Symposium. ASCO; San Francisco, January 2012. p. 140. [abstract: 367].
85. Peiffert D., Tournier-Rangeard L., Gerard J.P., et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 Trial. J Clin Oncol 2012, 30(16):1941-1948.
86. Glynne-Jones R., James R., Meadows H., et al. Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance CisP/5FU in squamous cell carcinoma of the anus: Results of ACT II. J Clin Oncol 2012, 30(suppl; abstr 4004).
87. Hwang J.M., Rao A.R., Cosmatos H.A., et al. Treatment of T3 and T4 anal carcinoma with combined chemoradiation and interstitial 192Ir implantation: a 10-year experience. Brachytherapy 2004, 3(2):95-100.
88. Chong G., Dickson J.L., Cunningham D., et al. Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer 2005, 93(5):510-514.
89. El-Ghazal R., Podoltsev N., Marks P., et al. Mitomycin-C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: cumulative toxicity of an old drug in a new era. Clin Colorectal Cancer 2011, 10(2):142-145.
90. Doci R., Zucali R., Bombelli L., et al. Combined chemoradiation therapy for anal cancer. A report of 56 cases. Ann Surg 1992, 215(2):150-156.
91. Gerard J.P., Ayzac L., Hun D., et al. Treatment of anal canal carcinoma with high dose radiation therapy and concomitant fluorouracil-cisplatinum. Long-term results in 95 patients. Radiother Oncol 1998, 46(3):249-256.
92. Hung A., Crane C., Delclos M., et al. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index. Cancer 2003, 97(5):1195-1202.
93. Olivatto L.O., Meton F., Bezerra M., et al. Phase I study of cetuximab (CET) in combination with 5-flurouracil (5FU), cisplatin (CP) and radiotherapy (RT) in patients with locally advanced squamous cell anal carcinoma (LAAC). J Clin Oncol 2008, 26:15S. [abstract 4609].
94. Matzinger O., Roelofsen F., Mineur L., et al. Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014). Eur J Cancer 2009, 45(16):2782-2791.
95. Adelstein D.J., Li Y., Adams G.L., et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003, 21(1):92-98.
96. Forastiere A.A., Goepfert H., Maor M., et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003, 349(22):2091-2098.
97. Loong H.H., Ma B.B., Leung S.F., et al. Prognostic significance of the total dose of cisplatin administered during concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Radiother Oncol 2012, [Epub ahead of print].
98. Eng C., Chang G.J., Das P., et al. Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOX-XRT) for squamous cell carcinoma of the anal canal. J Clin Oncol 2009, 27:15S. [abstract 4116].
99. Sadek H., Azli N., Wendling J.L., et al. Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer 1990, 66(8):1692-1696.
100. Meropol N.J., Niedzwiecki D., Shank B., et al. Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281). J Clin Oncol 2008, 26(19):3229-3234.
101. Peiffert D., Giovannini M., Ducreux M., et al. High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer: final results of a phase II study. Ann Oncol 2001, 12(3):397-404.
102. Choi C.H., Lee J.W., Kim T.J., et al. Phase II study of consolidation chemotherapy after concurrent chemoradiation in cervical cancer: preliminary results. Int J Radiat Oncol Biol Phys 2007, 68(3):817-822.
103. Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 2008, 26(35):5802-5812.
104. James R., Meadows H. The second UK phase IIII anal cancer trial of chemoradiation and maintenance therapy (ACT II): preliminary results on toxicity and outcome. Proc Am Soc Clin Oncol, J Clin Oncol 2003, 22:287. [abstract].
105. Hatfield P., Cooper R., Sebag-Montefiore D. Involved-field, low-dose chemoradiotherapy for early-stage anal carcinoma. Int J Radiat Oncol Biol Phys 2008, 70(2):419-424.
106. Hu K., Minsky B.D., Cohen A.M., et al. 30 Gy may be an adequate dose in patients with anal cancer treated with excisional biopsy followed by combined-modality therapy. J Surg Oncol 1999, 70(2):71-77.
107. Renehan A.G., O'Dwyer S.T. Management of local disease relapse. Colorectal Dis 2011, 13(s1):44-52.
108. Sebag-Montefiore D., James R., Meadows H., et al. The pattern and timing of disease recurrence in squamous cancer of the anus: Mature results from the NCRI ACT II trial. J Clin Oncol 2012, 30(suppl; abstr 4029).
109. Chapet O., Gerard J.P., Riche B., et al. Prognostic value of tumor regression evaluated after first course of radiotherapy for anal canal cancer. Int J Radiat Oncol Biol Phys 2005, 63(5):1316-1324.
110. Tanum G., Holm R. Anal carcinoma: a clinical approach to p53 and RB gene proteins. Oncology 1996, 53(5):369-373.
111. Schwarz J.K., Siegel B.A., Dehdashti F., et al. Tumor response and survival predicted by post-therapy FDG-PET/CT in anal cancer. Int J Radiat Oncol Biol Phys 2008, 71(1):180-186.
112. Chauveinc L., Buthaud X., Falcou M.C., et al. Anal canal cancer treatment: practical limitations of routine prescription of concurrent chemotherapy and radiotherapy. Br J Cancer 2003, 89(11):2057-2061.
113. Allal A.S., Mermillod B., Roth A.D., et al. Impact of clinical and therapeutic factors on major late complications after radiotherapy with or without concomitant chemotherapy for anal carcinoma. Int J Radiat Oncol Biol Phys 1997, 39(5):1099-1105.
114. Peiffert D., Bey P., Pernot M., et al. Conservative treatment by irradiation of epidermoid cancers of the anal canal: prognostic factors of tumoral control and complications. Int J Radiat Oncol Biol Phys 1997, 37(2):313-324.
115. Wagner J.P., Mahe M.A., Romestaing P., et al. Radiation therapy in the conservative treatment of carcinoma of the anal canal. Int J Radiat Oncol Biol Phys 1994, 29(1):17-23.
116. Glynne-Jones R., Sebag-Montefiore D., Adams R., et al. "Mind the gap" -the impact of variations in the duration of the treatment gap and overall treatment time in the first UK Anal Cancer Trial (ACT I). Int J Radiat Oncol Biol Phys 2011, 81(5):1488-1494.
117. Cox J.D., Stetz J., Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995, 31(5):1341-1346.
118. Northover J., Glynne-Jones R., Sebag-Montefiore D., et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer 2010, 102(7):1123-1128.
119. Baxter N.N., Habermann E.B., Tepper J.E., et al. Risk of pelvic fractures in older women following pelvic irradiation. JAMA 2005, 294(20):2587-2593.
120. Tomaszewski J.M., Link E., Leong T., et al. Twenty-five-year experience with radical chemoradiation for anal cancer. Int J Radiat Oncol Biol Phys 2012, 83(2):552-558.
121. Mai S.K., Welzel G., Haegele V., et al. The influence of smoking and other risk factors on the outcome after radiochemotherapy for anal cancer. Radiat Oncol 2007, 2:30.
122. Tournier-Rangeard L., Mercier M., Peiffert D., et al. Radiochemotherapy of locally advanced anal canal carcinoma: prospective assessment of early impact on the quality of life (randomized trial ACCORD 03). Radiother Oncol 2008, 87(3):391-397.
123. Allal A.S., Sprangers M.A., Laurencet F., et al. Assessment of long-term quality of life in patients with anal carcinomas treated by radiotherapy with or without chemotherapy. Br J Cancer 1999, 80(10):1588-1594.
124. Vordermark D., Sailer M., Flentje M., et al. Curative-intent radiation therapy in anal carcinoma: quality of life and sphincter function. Radiother Oncol 1999, 52(3):239-243.
125. Vordermark D., Sailer M., Flentje M., et al. Impaired sphincter function and good quality of life in anal carcinoma patients after radiotherapy: a paradox?. Front Radiat Ther Oncol 2002, 37:132-139.
126. Boman B.M., Moertel C.G., O'Connell M.J., et al. Carcinoma of the anal canal. A clinical and pathologic study of 188 cases. Cancer 1984, 54(1):114-125.
127. Kuehn P.G., Eisenberg H., Reed J.F. Epidermoid carcinoma of the perianal skin and anal canal. Cancer 1968, 22(5):932-938.
128. Wells I.T., Fox B.M. PET/CT in anal cancer-is it worth doing?. Clin Radiol 2012, 67(6):535-540.
129. Evans T.R., Lofts F.J., Mansi J.L., et al. A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer. Br J Cancer 1996, 73(10):1260-1264.
130. Ajani J.A., Carrasco C.H., Jackson D.E., et al. Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal. Am J Med 1989, 87(2):221-224.
131. Faivre C., Rougier P., Ducreux M., et al. Bull Cancer 1999, 86(10):861-865. [in French].
132. Fisher W.B., Herbst K.D., Sims J.E., et al. Metastatic cloacogenic carcinoma of the anus: sequential responses to adriamycin and cis-dichlorodiammineplatinum(II). Cancer Treat Rep 1978, 62(1):91-97.
133. Gurfinkel R., Walfisch S. Combined treatment of basaloid anal carcinoma using cisplatin, 5-fluorouracil and resection of hepatic metastasis. Tech Coloproctol 2005, 9(3):235-236.
134. Jaiyesimi I.A., Pazdur R. Cisplatin and 5-fluorouracil as salvage therapy for recurrent metastatic squamous cell carcinoma of the anal canal. Am J Clin Oncol 1993, 16(6):536-540.
135. Khater R., Frenay M., Bourry J., et al. Cisplatin plus 5-fluorouracil in the treatment of metastatic anal squamous cell carcinoma: a report of two cases. Cancer Treat Rep 1986, 70(11):1345-1346.
136. Salem P.A., Habboubi N., Anaissie E., et al. Effectiveness of cisplatin in the treatment of anal squamous cell carcinoma. Cancer Treat Rep 1985, 69(7-8):891-893.
137. Tanum G., Tveit K., Karlsen K.O., et al. Chemotherapy and radiation therapy for anal carcinoma. Survival and late morbidity. Cancer 1991, 67(10):2462-2466.
138. Hainsworth J.D., Burris H.A., Meluch A.A., et al. Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a Phase II trial. Cancer 2001, 92(3):642-649.
139. Jhawer M., Mani S., Lefkopoulou M., et al. Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and Bleomycin-CCNU in patients with advanced cancer of the anal canal: an Eastern Cooperative Oncology Group study E7282. Invest New Drugs 2006, 24(5):447-454.
140. Wilking N., Petrelli N., Herrera L., et al. Phase II study of combination bleomycin, vincristine and high-dose methotrexate (BOM) with leucovorin rescue in advanced squamous cell carcinoma of the anal canal. Cancer Chemother Pharmacol 1985, 15(3):300-302.
141. Tanum G. Treatment of relapsing anal carcinoma. Acta Oncol 1993, 32(1):33-35.
142. Golub D.V., Civelek A.C., Sharma V.R. A regimen of taxol, Ifosfamide, and platinum for recurrent advanced squamous cell cancer of the anal canal. Chemother Res Pract 2011, 2011:163736.
143. Vuong T., Devic S., Belliveau P., et al. Contribution of conformal therapy in the treatment of anal canal carcinoma with combined chemotherapy and radiotherapy: results of a phase II study. Int J Radiat Oncol Biol Phys 2003, 56(3):823-831.
144. Moreau-Claeys M.V., Peiffert D. Cancer Radiother 2010, 14(4-5):359-362. [in French].
145. Salama J.K., Mell L.K., Schomas D.A., et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol 2007, 25(29):4581-4586.
146. Mell L.K., Schomas D.A., Salama J.K., et al. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2008, 70(5):1431-1437.
147. Alvarez G., Perry A., Tan B.R., et al. Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification. Mod Pathol 2006, 19(7):942-949.
148. Van Damme N., Deron P., Van Roy N., et al. Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. BMC Cancer 2010, 10:189.
149. Bussink J., van der Kogel A.J., Kaanders J.H. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 2008, 9(3):288-296.
150. Miyaguchi M., Olofsson J., Hellquist H.B. Expression of epidermal growth factor receptor in glottic carcinoma and its relation to recurrence after radiotherapy. Clin Otolaryngol Allied Sci 1991, 16(5):466-469.
151. Bosset J.F., Roelofsen F., Morgan D.A., et al. Shortened irradiation scheme, continuous infusion of 5-fluorouracil and fractionation of mitomycin C in locally advanced anal carcinomas. Results of a phase II study of the European Organization for Research and Treatment of Cancer. Radiotherapy and Gastrointestinal Cooperative Groups. Eur J Cancer 2003, 39(1):45-51.
152. Glynne-Jones R., Meadows H., Wan S., et al. EXTRA-a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. Int J Radiat Oncol Biol Phys 2008, 72(1):119-126.
153. Zampino M.G., Magni E., Sonzogni A., et al. K-ras status in squamous cell anal carcinoma (SCC): it's time for target-oriented treatment?. Cancer Chemother Pharmacol 2009, 65(1):197-199.
154. Lukan N., Strobel P., Willer A., et al. Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology 2009, 77(5):293-299.
155. Kronfli M., Glynne-Jones R. Chemoradiotherapy in anal cancer. Colorectal Dis 2011, 13(Suppl 1):33-38.
156. Sischy B., Doggett R.L.S., Krall J.M., et al. Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: interim report on Radiation Therapy Oncology Group study no 8314. J Natl Cancer Inst 1989, 81:850-856.
157. Martenson J.A., Lipsitz S.R., Wagner H., et al. Initial results of a phase II trial of high dose radiation therapy, 5-fluorouracil, and cisplatin for patients with anal cancer (E4292). Int J Radiation Oncol Biol Phys 1996, 35:745-749.
158. Doci R., Zucali R., La Monica G., et al. Primary chemoradiation therapy with fluorouracil and cisplatin for cancer of the anus: results in 35 consecutive patients. J Clin Oncol 1996, 14:3121-3125.
159. Konski A., Garcia M., John M., et al. Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of of RTOG 92-08. Int J Radiat Oncol Biol Phys 2008, 72(1):114-118.
160. Vaz F., Trindade C., Barata A., et al. Sequential and concomitant chemoradiation (CTR) therapy with flurouracil (5FU) and cisplatin (CDDP) for anal squamous cell carcinoma (ASCC). J Clin Oncol 1998, 17:304. [abstract 1173].
161. Gerard J.P., Romestaing P., Mornex F., et al. Radiochemotherapy in anal carcinoma (ACC). A randomised trial comparing fluorouracil-cisplatin (5FU-CDDP) and CDDP alone. Eur J Cancer 1999, S143. [abstract 523].
162. Matthews J.H., Burmeister B.H., Borg M., et al. T1-2 anal carcinoma requires elective inguinal radiation treatment-the results of Trans Tasman Radiation Oncology Group study TROG 99.02. Radiother Oncol 2011, 98(1):93-98.
163. Sebag-Montefiore D., Meadows H.M., Cunningham D., et al. Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): Long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin. Radiother Oncol 2012 Aug, 104(2):155-160.
164. Crehange G., Bosset M., Lorchel F., et al. Combining cisplatin and Mitomycin with radiotherapy in anal carcinoma. Dis Colon Rectum 2006, 50:43-49.
165. Kachnic L., Winter K., Myerson R., et al. Early efficacy of RTOG-0529: a phase II evaluation of dose painted IMRT in combination with 5-fluorouracil and Mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiation Oncol Biol Phys 2010, 78(3S). suppl PROC ASTRO:s55. [abstract 116].